- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00158912
VAST - Ventricular Arrhythmia Suppression Trial
November 20, 2006 updated by: Boston Scientific Corporation
Ventricular Arrhythmia Suppression Trial
The purpose of VAST is to determine whether the Rate Smoothing feature in Guidant's PRIZM/VITALITY-family ICDs has an effect on the incidence of ventricular tachyarrhythmias.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
550
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who receive a commercially available Guidant PRIZM, PRIZM 2, or VITALITY AVT ICD
- Patients who sign and date a Patient Informed Consent prior to study enrollment
- Patients who remain in the clinical care of physicians of their implanting center
Exclusion Criteria:
- Patients who have chronic atrial fibrillation. Paroxysms of AF are not an exclusion criterion, but the patient must be in normal sinus rhythm at the time of randomization. If history of AF is unknown or uncertain, or the patient was recently cardioverted, there must be at least 23 hours of normal sinus rhythm within the 24 hour period preceding randomization
- Patients who previously had an ICD
- Patients with current indications for cardiac resynchronization therapy with defibrillation (CRT-D)
- Patients whose life expectancy is less than 12 months due to other medical conditions
- Patients who are expected to receive a heart transplant during the duration of the study
- Patients who have or who are likely to receive a tricuspid or other valve prosthesis
- Patients who are currently enrolled in another investigational study of active medical therapy. Each instance should be brought to Guidant's Clinical Application Research Studies (CARS) group to determine eligibility
- Patients who are younger than 18 years of age
- Patients who are mentally incompetent and cannot give a Patient Informed Consent or participate in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary endpoint for this study will be the number of episodes of ventricular tachyarrhythmia in each patient during each follow-up period (ON vs. OFF treatment).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2003
Study Completion
May 1, 2005
Study Registration Dates
First Submitted
September 7, 2005
First Submitted That Met QC Criteria
September 11, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
November 22, 2006
Last Update Submitted That Met QC Criteria
November 20, 2006
Last Verified
November 1, 2006
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-CA-060903-T
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tachycardia
-
Erasmus Medical CenterUnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, SupraventricularNetherlands
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart Disease | Supraventricular Tachycardia | AtrioVentricular Nodal Reentrant TachycardiaUnited States, Canada
-
Parc de Salut MarNot yet recruitingSupraventricular Tachycardia | Atrioventricular Nodal Re Entrant TachycardiaSpain
-
University of PretoriaCompletedSupra-ventricular TachycardiaSouth Africa
-
Princess Margaret Hospital, Hong KongUnknownSupraventricular Tachycardia | Atrioventricular Nodal Reentrant TachycardiaChina
-
Milestone Pharmaceuticals Inc.Medpace, Inc.CompletedParoxysmal Supraventricular Tachycardia (PSVT)United States, Canada
-
Milestone Pharmaceuticals Inc.TerminatedParoxysmal Supraventricular Tachycardia (PSVT)United States
-
University Hospital, ToulouseRecruitingSupraventricular Tachycardia | Atrioventricular Nodal Reentry TachycardiaFrance
-
University Hospital of FerraraRecruitingAtrioventricular Nodal Re Entrant TachycardiaItaly
-
Milestone Pharmaceuticals Inc.RecruitingParoxysmal Supraventricular TachycardiaUnited States
Clinical Trials on Implantable Cardioverter Defibrillator
-
Boston Scientific CorporationCompleted
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedHeart DiseasesUnited States
-
Boston Scientific CorporationCompleted
-
Population Health Research InstituteBoston Scientific CorporationCompleted
-
Medtronic Bakken Research CenterAstraZenecaCompletedAcute Myocardial InfarctionNetherlands
-
Rennes University HospitalCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedVentricular ArrhythmiasGermany, United States, Denmark, Canada, Netherlands, Switzerland, Austria
-
Maurizio Eugenio LandolinaRecruitingAppropriate and Inappropriate Shock Therapy With ICD | Arrhythmias DetectionItaly
-
Deutsches Herzzentrum MuenchenCompleted
-
Biotronik SE & Co. KGCompletedTachyarrhythmiaGermany, Switzerland